DaVita Inc.

Revenue comes mainly from payment per dialysis treatment, billed either as a bundled rate or as separate fees for treatment and drugs, with hospitals paying their own negotiated per-treatment fees. A smaller layer comes from management fees tied to a share of affiliated centers' revenue or collections, and from integrated-care contracts paid through shared savings, performance-based fees, or a fixed amount per covered member.

CompanyGraph reads DaVita's growth as scaling by replicating a largely standardized treatment center, opening more domestic and international centers, sometimes through joint ventures with local partners, while reinvesting in existing sites. That expansion sits on a debt-heavy capital structure, where borrowed capital is large relative to cash flow and equity, so returns are boosted by leverage layered on top of whatever the underlying centers earn on their own, a pattern that has coincided with several straight years of revenue, profit and net income growth.

Its own account describes dependence on commercial insurance payors that pay above government rates, a limited pool of suppliers for dialysis equipment, parts, pharmaceuticals and certain home-dialysis supplies, the nephrologists and medical directors who refer and oversee patient care, outside providers of claims-processing and information-technology services, and continued government reimbursement. CompanyGraph also maps it as sitting downstream of a wider set of supplying industries, consistent with a business built on continuous physical and clinical inputs rather than one-time purchases.

Patients who need recurring kidney-failure treatment are its direct dependents, along with hospitals that contract with it for inpatient dialysis and, by its own account, the Department of Veterans Affairs under a national dialysis services contract. Health plans, Medicare and Medicaid programs, and drug companies running clinical research also depend on it, either to deliver contracted care to their members or to reach this patient population for study.

CompanyGraph places DaVita's underlying economics, capital-heavy operations paid per unit of service delivered, within a very large group of similarly built companies, so that basic shape by itself is not unusual. DaVita's own account instead points to its network of licensed centers, its relationships with referring nephrologists, and its recorded standing in government quality-rating programs as what it considers its strengths, though nothing on file shows whether competitors could or could not reproduce them.

DaVita's own account names clinical staffing, specifically nationwide shortages of nurses and other skilled clinical personnel, along with the supply of qualified medical directors, Medicare certification, adequate payor reimbursement, and a limited supplier base for certain home-dialysis supplies, as what can limit how far it is able to expand. CompanyGraph also tests this against a general expectation for businesses of this kind, that growth is bound by how much fixed treatment capacity can process, and finds the company's own framing centred more on people and approvals than on physical processing capacity.

DaVita's own account states that commercial insurance payments, coming from a minority of its patients, generate nearly all of its profit, while most patients are covered by government programs paying at lower rates, so a shift in that mix or in reimbursement bears directly on profitability. It also flags reliance on a limited pool of suppliers for certain home-dialysis supplies and on outside parties for claims-processing and information-technology services as points where its operations depend on others it does not control.

By its own account, DaVita operates under certification and licensing from CMS and state health and Medicaid authorities, with additional oversight from occupational-safety, food and drug, trade and civil-rights or inspector-general regulators. It also discloses ongoing government investigations and litigation that it says it disputes, along with trade-policy and currency risks tied to its international centers, exposure it has chosen not to hedge.